Holen Sie sich die Stockscreener-App
87.87
4.81%
-4.44
Handel nachbörslich:
88.07
0.20
+0.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$92.31
Offen:
$92.31
24-Stunden-Volumen:
20.48M
Relative Volume:
1.45
Marktkapitalisierung:
$235.20B
Einnahmen:
$64.17B
Nettoeinkommen (Verlust:
$17.12B
KGV:
13.06
EPS:
6.73
Netto-Cashflow:
$18.10B
1W Leistung:
-7.23%
1M Leistung:
-3.89%
6M Leistung:
-23.41%
1J Leistung:
-29.88%
1-Tages-Spanne:
$87.08
$92.31
1-Wochen-Bereich:
$87.08
$95.43
52-Wochen-Spanne:
$81.04
$134.63
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Vergleichen Sie MRK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
87.87 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
852.35 | 765.56B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.34 | 355.44B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
73.60 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
GME, KBSX, MRK, UPS, TSLA: Top 5 Trending Stocks TodayGameStop (NYSE:GME) - Benzinga
Merck Doubles Down On Oral Lipid-Lowering Drugs With Hengrui’s Lp(a) Asset - Scrip
Why Pharma and Biotech Stocks Got Thrashed on Tuesday - The Motley Fool
Is Merck & Co. Inc. (MRK) The Best Defensive Stock Amid Market Volatility? - Insider Monkey
Merck Makes Bold $2B Bet on Chinese Cardio Drug - USA Herald
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors - MSN
For nearly $2B, Jiangsu Hengrui licenses heart drug to Merck - BioWorld Online
Merck Betting Up To $2B On China-Developed Cardio Drug - Law360
Merck & Co Inc (MRK) Trading Down 3.66% on Mar 25 - GuruFocus.com
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment - Benzinga
Merck Strikes Nearly $2 Billion Licensing Deal For Chinese Firm's Heart Disease Drug Candidate - Marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck inks a licensing deal worth nearly $2B with China’s Jiangsu Hengrui - Seeking Alpha
Merck Will Pay Up to $2 Billion for Chinese Heart Drug Rights - Bloomberg
Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Merck buys rights to heart disease drug in latest China deal - Marketscreener.com
Merck Enters Exclusive License Agreement For HRS-5346 From Jiangsu Hengrui Pharmaceuticals - Marketscreener.com
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. - Business Wire
Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Merck & Co. sees ratings upgrade to Aa3 by Moody’s Ratings - Investing.com
Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (Fed. Cir. 2025) - JD Supra
MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein - GlobeNewswire
Is Merck & Co. (MRK) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
MRK LAWSUIT ALERT: The Gross Law Firm Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - TradingView
Merck & Co. (MRK): Among Stocks Insiders Were Piling Into Recently - Yahoo Finance
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - PR Newswire
Lyophilized Product Market to Witness Remarkable Growth with - openPR
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRK - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - PR Newswire
Merck & Co., Inc. (MRK): Among Incredibly Cheap Dividend Stock to Buy Now - Insider Monkey
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
Why Merck & Co. (MRK) Is Among the Most Undervalued Biotech Stocks to Invest In - Yahoo Finance
Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsMRK - ACCESS Newswire
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Markets Insider
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Merck & Co's Options: A Look at What the Big Money is Thinking - Benzinga
Class Action Filed Against Merck & Co., Inc. (MRK)April 14, 2025 Deadline to Join – Contact Levi & Korsinsky - GlobeNewswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Is Merck & Co Inc. (NYSE:MRK) the Most Undervalued S&P 500 Stock to Buy Now? - Yahoo Finance
Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025MRK - PR Newswire
Is Merck & Co Inc. (NYSE:MRK) the Most Profitable Value Stock to Buy Now? - Insider Monkey
Shareholders that lost money on Merck & Co., Inc.(MRK) - GlobeNewswire
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):